• PFE

Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund

Pfizer appeals a judge's rejection of its claim for $75.2 million from an insider trading settlement linked to SAC Capital Management and Mathew Martoma's trades.

• BIIB
• JNJ
• LLY
• NBI
• NVO
• PFE
• US500

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

The biopharmaceutical industry seeks to rebound in 2025, navigating uncertainty from regulatory changes and potential impacts from President Trump's administration on drug pricing and vaccine policies.

• BNTX
• PFE

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

• ACI
• AFRM
• COIN
• MSTR
• NVDA
• PFE
• SEDG
• STLA

Nvidia, Evgo and Affirm fall premarket; Pfizer and SolarEdge rise

US stock futures fell ahead of the Federal Reserve meeting, with notable movers including Nvidia, Pfizer, and Evgo impacting market dynamics.

• PFE

Pfizer projects 2025 earnings to align with expectations

Pfizer anticipates 2025 profits will align with Wall Street expectations amid a company strategy to cut costs following declining sales and investor criticisms.

• PFE

Pfizer does not expect major vaccine policy changes under Trump in 2025

• CI
• CVS
• LLY
• PFE
• UNH

Insurer stocks fall after Trump says 'we're going to knock out the middleman'

Trump's criticism of pharmacy benefit managers caused shares of major health insurers to drop, igniting debate about drug pricing and proposals to eliminate middlemen in the industry.

• EXEL
• GILD
• JNJ
• MRK
• NOVN
• PFE

Unsupported price hikes added $815 million to US drug spending in 2023

A report reveals five drugs accounted for $815 million in U.S. spending increases in 2023 without clinical evidence, highlighting ongoing pricing issues in the pharmaceutical industry.

• AMZN
• NYT
• PFE
• UNH

Health execs reckon with patient outrage after UnitedHealthcare killing

Health care executives reassess patient experiences and security after the murder of UnitedHealth CEO Brian Thompson, deepening dialogue on healthcare corruption and systemic issues.

• LLY
• PFE

Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump

Eli Lilly's CEO emphasized drug affordability and regulatory reforms as key focuses for a second Trump term, discussing potential collaborations in healthcare and cost reduction strategies.